


Aurora Kinases-IN-2

Cat. No.:	HY-150592
CAS No.:	2241914-86-1
Molecular Formula:	C ₂₂ H ₁₈ ClN ₅ O ₃
Molecular Weight:	435.86
Target:	Aurora Kinase
Pathway:	Cell Cycle/DNA Damage; Epigenetics
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Aurora Kinases-IN-2 (compound 12Aj) is a potent Aurora kinases inhibitor with IC ₅₀ values of 90 and 152 nM for Aurora A and Aurora B. Aurora Kinases-IN-2 arrests cell cycle at G2/M phase by regulating cyclin B1 and cdc2. Aurora Kinases-IN-2 can be used for cancer research ^[1] .									
IC₅₀ & Target	Aurora A 90 nM (IC ₅₀)	Aurora B 152 nM (IC ₅₀)								
In Vitro	<p>Aurora Kinases-IN-2 (compound 12Aj) (72 hours) has antiproliferative activity with IC₅₀ values of 11.5 μM, 1.34 μM, 7.30 μM and 1.64 μM for U87, HeLa, HepG2 and LoVo tumor cell lines, respectively^[1].</p> <p>Aurora Kinases-IN-2 (compound 12Aj) (0-10 μM; 24 hours) inhibits Aurora A and Aurora B in HeLa cells^[1].</p> <p>Aurora Kinases-IN-2 (compound 12Aj) (0-10 μM; 24 hours; HeLa cells) results in G2/M accumulation by regulating the expression of Cyclin B1 and cdc2^[1].</p> <p>Aurora Kinases-IN-2 (compound 12Aj) (0-10 μM; 24 hours) blocks phosphorylation of Aurora kinases in HeLa cells^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Western Blot Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>HeLa cells</td> </tr> <tr> <td>Concentration:</td> <td>0, 1, 5 and 10 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 hours</td> </tr> <tr> <td>Result:</td> <td>Decreased the expression level of Aurora A and B, as well as reduced phosphorylation of Aurora A on Thr288 (p-Thr288) and Aurora B on Thr232 (p-Thr232) in a dose-dependent manner.</td> </tr> </table>		Cell Line:	HeLa cells	Concentration:	0, 1, 5 and 10 μM	Incubation Time:	24 hours	Result:	Decreased the expression level of Aurora A and B, as well as reduced phosphorylation of Aurora A on Thr288 (p-Thr288) and Aurora B on Thr232 (p-Thr232) in a dose-dependent manner.
Cell Line:	HeLa cells									
Concentration:	0, 1, 5 and 10 μM									
Incubation Time:	24 hours									
Result:	Decreased the expression level of Aurora A and B, as well as reduced phosphorylation of Aurora A on Thr288 (p-Thr288) and Aurora B on Thr232 (p-Thr232) in a dose-dependent manner.									

REFERENCES

[1]. Bo YX, et, al. Synthesis, biological evaluation and molecular modeling study of 2-amino-3,5-disubstituted-pyrazines as Aurora kinases inhibitors. *Bioorg Med Chem.* 2020 Mar 1;28(5):115351.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA